Segment Information

9 Months Ended

Mar. 31, 2013

Segment Information

(9)  Segment Information

The Company’s business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.  In fiscal 2012, the Company reconfigured and renamed its three business segments to more accurately reflect the scope of its business activities. As such, the Company has recasted the segment information as if the composition of its reportable segments had existed in the prior period presented.

Human Health - includes finished dosage form generic drugs and nutraceutical products.

Pharmaceutical Ingredients – includespharmaceutical intermediates and active pharmaceutical ingredients (APIs).

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agriculture Protection Products. Specialty chemicals includes a variety of chemicals which make plastics, surface coatings, textiles, fuels and lubricants perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals. In addition, Aceto is a supplier of diazos and couplers to the paper, film and electronics industries.

Agricultural Protection Products includes herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. The Agricultural Protection Products segment also includes a sprout inhibitor for potatoes and an herbicide for sugar cane.

The Company’s chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments’ performance, as the assets are managed on an entity-wide basis.

Nine Months Ended March 31, 2013 and 2012:

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2013
Net sales	$	92,559	$	142,169	$	141,847	$	-		$	376,575
Gross profit		28,062		25,429		20,249		-			73,740
Income (loss) before income taxes		12,760		12,432		8,391		(7,276	)		26,307
2012
Net sales	$	78,243	$	121,537	$	133,659	$	-		$	333,439
Gross profit		22,860		18,654		19,804		-			61,318
Income (loss) before income taxes		9,836		5,839		7,940		(4,164	)		19,451

Three Months Ended March 31, 2013 and 2012:

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2013
Net sales	$	36,299	$	61,776	$	52,796	$	-		$	150,871
Gross profit		11,052		13,382		7,093		-			31,527
Income (loss) before income taxes		5,389		8,794		3,010		(5,606	)		11,587
2012
Net sales	$	28,182	$	40,580	$	52,653	$	-		$	121,415
Gross profit		7,798		6,185		8,172		-			22,155
Income (loss) before income taxes		2,990		1,890		3,849		(1,181	)		7,548